Microbot Medical Inc. (CY9D.F)
- Previous Close
2.1200 - Open
2.1460 - Bid 2.1080 x --
- Ask 2.1940 x --
- Day's Range
2.1460 - 2.1460 - 52 Week Range
0.7000 - 3.7000 - Volume
1,315 - Avg. Volume
90 - Market Cap (intraday)
80.768M - Beta (5Y Monthly) 1.15
- PE Ratio (TTM)
-- - EPS (TTM)
-0.6500 - Earnings Date May 16, 2025 - May 22, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Microbot Medical Inc., a clinical-stage medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space in Israel and the United States. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, endovascular, and neurovascular operations. It also provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter. The company has a collaboration agreement with Corewell Health for the development of LIBERTY endovascular robotic system; and Emory University, in connection with autonomous robotics in endovascular procedures. Microbot Medical Inc. was founded in 2010 and is based in Hingham, Massachusetts.
microbotmedical.comRecent News: CY9D.F
View MorePerformance Overview: CY9D.F
Trailing total returns as of 5/15/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CY9D.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CY9D.F
View MoreValuation Measures
Market Cap
79.79M
Enterprise Value
75.00M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
24.37
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-101.21%
Return on Equity (ttm)
-284.97%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-11.44M
Diluted EPS (ttm)
-0.6500
Balance Sheet and Cash Flow
Total Cash (mrq)
5.47M
Total Debt/Equity (mrq)
3.14%
Levered Free Cash Flow (ttm)
-5.87M